A new player has entered the liquid biopsy game.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
The cancer blood testing company Laboratory for Advanced Medicine is ready to compete on price, which might be necessary in a market already thronged with products.
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.